Raymond James & Associates Decreases Stake in argenx SE (NASDAQ:ARGX)

Raymond James & Associates lessened its stake in argenx SE (NASDAQ:ARGXFree Report) by 1.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,312 shares of the company’s stock after selling 459 shares during the quarter. Raymond James & Associates owned 0.06% of argenx worth $12,673,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Massachusetts Financial Services Co. MA lifted its position in shares of argenx by 339.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 581,586 shares of the company’s stock valued at $285,925,000 after acquiring an additional 449,151 shares during the period. Morgan Stanley raised its holdings in argenx by 236.9% during the fourth quarter. Morgan Stanley now owns 630,330 shares of the company’s stock worth $238,788,000 after purchasing an additional 443,217 shares during the last quarter. Jennison Associates LLC boosted its position in argenx by 32.2% during the third quarter. Jennison Associates LLC now owns 1,511,745 shares of the company’s stock worth $743,219,000 after purchasing an additional 368,367 shares in the last quarter. Invesco Ltd. grew its holdings in argenx by 377.0% in the third quarter. Invesco Ltd. now owns 430,787 shares of the company’s stock valued at $211,788,000 after purchasing an additional 340,482 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of argenx by 185.1% in the first quarter. Bank of America Corp DE now owns 297,832 shares of the company’s stock valued at $110,966,000 after buying an additional 193,353 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Evercore ISI lowered their price objective on shares of argenx from $594.00 to $436.00 and set an “outperform” rating on the stock in a research note on Thursday, December 21st. Raymond James dropped their price objective on shares of argenx from $580.00 to $520.00 and set a “strong-buy” rating for the company in a research note on Thursday, December 21st. Wolfe Research started coverage on argenx in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. Stifel Nicolaus raised their price target on argenx from $557.00 to $560.00 and gave the stock a “buy” rating in a research report on Monday, December 18th. Finally, TD Cowen boosted their price target on argenx from $612.00 to $641.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $530.74.

View Our Latest Stock Report on argenx

argenx Stock Performance

argenx stock opened at $398.49 on Thursday. argenx SE has a 1 year low of $327.73 and a 1 year high of $550.76. The firm has a 50 day moving average price of $390.30 and a 200 day moving average price of $430.80. The company has a market cap of $23.63 billion, a price-to-earnings ratio of -77.53 and a beta of 0.65.

argenx (NASDAQ:ARGXGet Free Report) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The company had revenue of $417.84 million for the quarter, compared to analysts’ expectations of $378.60 million. argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. During the same period in the prior year, the firm earned ($0.70) earnings per share. Sell-side analysts predict that argenx SE will post -2 EPS for the current year.

argenx Company Profile

(Free Report)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.

Featured Articles

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE (NASDAQ:ARGXFree Report).

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.